CNO Stock Analysis: CNO Financial | NYSE
Insurance - Life | NYSE, USA | Market Cap: 5.065m USD | 12M Return: 41.9% | US12621E1038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 48.6M
EPS Trend: 89.5%
Qual. Beats: 2
Rev. Trend: 80.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CNO Financial Group is a U.S. life and health insurer that develops, markets, and administers insurance and annuity products aimed primarily at middle-income pre-retiree and retired Americans. Its product portfolio spans Medicare supplement, supplemental health, long-term care insurance, Medicare advantage plans, fixed and fixed indexed annuities, and a range of life insurance products including universal life, whole life, term life, and graded benefit policies. Distribution occurs through phone, online, virtual, and face-to-face agent channels, as well as through workplace-based voluntary benefit programs sold to businesses, associations, and membership groups.
The company markets under three primary brands: Bankers Life, Washington National, and Colonial Penn. Founded in 1979 and headquartered in Carmel, Indiana, CNO has been publicly traded on the NYSE since 1987 and operates within the Life & Health Insurance sub-industry of the Financials sector. Its focus on the middle-income senior demographic distinguishes it from larger carriers that serve a broader or higher-net-worth customer base, with annuities and supplemental health products representing core sources of premium and fee income for this segment of the industry.
- Medicare supplement enrollment expands with aging middle-income population
- Fixed indexed annuity sales accelerate amid rising rate environment
- Long-term care reserve releases and share repurchases support capital returns
| Net Income: 417.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.29 > 1.0 |
| NWC/Revenue: -406.9% < 20% (prev -109.5%; Δ -297.4% < -1%) |
| CFO/TA 0.02 > 3% & CFO 743.1m > Net Income 417.6m |
| Net Debt (3.39b) to EBITDA (864.4m): 3.92 < 3 |
| Current Ratio: 0.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (94.3m) vs 12m ago -4.41% < -2% |
| Gross Margin: 45.48% > 18% (prev 40.31%; Δ 5.16% > 0.5%) |
| Asset Turnover: 11.72% > 50% (prev 11.60%; Δ 0.12% > 0%) |
| Interest Coverage Ratio: 2.51 > 6 (EBIT TTM 545.9m / Interest Expense TTM 217.5m) |
| A: -0.47 (Total Current Assets 1.42b - Total Current Liabilities 19.9b) / Total Assets 39.2b |
| B: 0.07 (Retained Earnings 2.69b / Total Assets 39.2b) |
| C: 0.01 (EBIT TTM 545.9m / Avg Total Assets 38.8b) |
| D: 8.06 (Book Value of Equity 2.32b / Total Liabilities 288.4m) |
| Altman-Z'' = 5.69 = AAA |
As of November 10, 2026, the stock is trading at USD 57.16 with a total of 665,189 shares traded. Over the past week, the price has changed by -2.27%, over one month by +7.87%, over three months by +3.72% and over the past year by +41.89%.
Current recommended Stop Loss: 53.70 (which is 6.1% or 2.6 ATR below the current price).
CNO Financial has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CNO.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 56.8 | -0.7% |
P/E Trailing = 12.7471
P/E Forward = 9.7087
P/S = 1.1148
P/B = 2.1884
P/EG = 1.287
Revenue TTM = 4.54b USD
EBIT TTM = 545.9m USD
EBITDA TTM = 864.4m USD
Long Term Debt = 4.05b USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 4.81b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.39b USD (calculated: Debt 4.81b - CCE 1.42b)
Enterprise Value = 8.46b USD (5.07b + Debt 4.81b - CCE 1.42b)
Interest Coverage Ratio = 2.51 (Ebit TTM 545.9m / Interest Expense TTM 217.5m)
EV/FCF = 11.38x (Enterprise Value 8.46b / FCF TTM 743.1m)
FCF Yield = 8.79% (FCF TTM 743.1m / Enterprise Value 8.46b)
FCF Margin = 16.35% (FCF TTM 743.1m / Revenue TTM 4.54b)
Net Margin = 9.19% (Net Income TTM 417.6m / Revenue TTM 4.54b)
Gross Margin = 45.48% ((Revenue TTM 4.54b - Cost of Revenue TTM 2.48b) / Revenue TTM)
Gross Margin QoQ = none% (prev 43.42%)
Tobins Q-Ratio = 0.22 (Enterprise Value 8.46b / Total Assets 39.2b)
Interest Expense / Debt = 4.52% (Interest Expense 217.5m / Debt 4.81b)
Taxrate = 23.50% (128.3m / 545.9m)
NOPAT = 417.6m (EBIT 545.9m * (1 - 23.50%))
Current Ratio = 0.07 (Total Current Assets 1.42b / Total Current Liabilities 20.0b)
Debt / Equity = 2.07 (Debt 4.81b / totalStockholderEquity, last quarter 2.32b)
Debt / EBITDA = 3.92 (Net Debt 3.39b / EBITDA 864.4m)
Debt / FCF = 4.56 (Net Debt 3.39b / FCF TTM 743.1m)
Total Stockholder Equity = 2.51b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.08% (Net Income 417.6m / Total Assets 39.2b)
RoE = 16.62% (Net Income TTM 417.6m / Total Stockholder Equity 2.51b)
RoCE = 8.32% (EBIT 545.9m / Capital Employed (Equity 2.51b + L.T.Debt 4.05b))
RoIC = 1.07% (NOPAT 417.6m / Invested Capital 39.0b)
WACC = 5.40% (E(5.07b)/V(9.88b) * Re(7.24%) + D(4.81b)/V(9.88b) * Rd(4.52%) * (1-Tc(0.24)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.95 | Cagr: -6.35%
[DCF] Terminal Value 77.97% ; FCFF base≈692.0m ; Y1≈793.2m ; Y5≈1.17b
[DCF] Fair Price = 155.2 (EV 17.6b - Net Debt 3.39b = Equity 14.2b / Shares 91.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 89.53 | EPS CAGR: 14.89% | SUE: 2.75 | # QB: 2
Revenue Correlation: 80.25 | Revenue CAGR: 2.80% | SUE: 0.33 | # QB: 0
EPS current Quarter (2027-03-31): EPS=1.11 | Chg30d=+9.31% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=5.57 | Chg30d=+19.16% | Revisions=+25% | GrowthEPS=+26.5% | GrowthRev=-8.1%
EPS next Year (2027-12-31): EPS=5.14 | Chg30d=+2.15% | Revisions=+25% | GrowthEPS=-7.7% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +17% (up=2, down=1)